The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
The preeminence of mRNA and viral vector-based vaccines in the COVID-19 pandemic response has begun reshaping the global biopharmaceutical manufacturing infrastructure. The number, speed, and scale of manufacturing investments in these COVID-19 vaccines reflect both the proven potential of ATMP modalities as well as the vast implications for bio-manufacturers as they seek to simultaneously meet current demand and future-proof their manufacturing infrastructure. This presentation will explain the new modalities, describe the specific processes involved in their production, and provide a perspective on the challenges involved in, and solutions needed for, successfully adapting today’s manufacturing infrastructure. This presentation is intended for those involved in the design, construction, and operation of biopharmaceutical facilities as well as researchers/scientists interested in understanding the impact of ATMP modalities on the pharma manufacturing industry.
